AIDS 2010--XVIII International AIDS Conference.
The AIDS 2010-XVIII International AIDS Conference, held in Vienna, included topics covering new therapeutic developments in the field of HIV therapy. This conference report highlights selected presentations on novel HIV entry inhibitors, reverse transcriptase inhibitors, integrase inhibitors and clinical trial data for an NRTI-based, antiviral, hyperactivation-limiting therapeutic. Investigational drugs discussed include GSK-1349572 (Viiv Healthcare/Shionogi & Co Ltd) and VS-411 (ViroStatics).
Desimmie
Belete A
BA
Katholieke Universiteit Leuven, Lab Moleculaire Virologie & Gentherapie, Kapucijnenvoer 33, Leuven, Belgium. belete.desimmie@med.kuleuven.be
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D015195:Drug Design; D015507:Drugs, Investigational / Q000494:pharmacology*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans
D019380:Anti-HIV Agents; D015507:Drugs, Investigational